Nanosonics Limited ( (AU:NAN) ) has provided an update.
Nanosonics Limited announced a change in the director’s interest notice due to an acquisition of performance rights by CEO Michael Kavanagh. The company acknowledged a delay in lodging the notice due to an administrative oversight and has since reviewed its procedures to ensure compliance with ASX listing rules.
More about Nanosonics Limited
Nanosonics Limited operates in the healthcare industry, specializing in infection prevention solutions. The company is known for its innovative disinfection products and services, primarily focusing on ultrasound probe disinfection systems.
YTD Price Performance: 49.73%
Average Trading Volume: 853
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $845.6M
For an in-depth examination of NAN stock, go to TipRanks’ Stock Analysis page.